GENSPERA, INC. (OTCBB:GNSZ):is a development stage oncology company focused on therapeutics that deliver a potent, unique and patented drug directly to tumors. GenSpera's technology platform combines a potent, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that releases the drug only within the tumor. Unlike standard cancer drugs, thapsigargin kills cells independent of their division rate, thus making it effective at killing all fast- and slow-growing cancers and cancer stem cells. GenSpera's prodrug platform is the subject of seven issued patents with four additional patents pending. Visit: http://www.genspera.com for more information.

INFUSYSTEM HOLDING, INC. (OTCBB:INHI): is the leading supplier of infusion services to oncologists and other outpatient treatment settings. The Company provides pole mounted and ambulatory pumps, supplies and related clinical, biomedical and billing services to practices and patients, nationwide. The Company's unique suite of services appeals to practices, patients and payors by improving access to clinically necessary medical equipment, while driving down costs and maximizing clinical outcomes. Visit http://www.infusystem.com for more information.

DISCLAIMER: LDV Capital Management is a Registered Investment Advisory firm licensed with the State of Florida. The information herein is not a solicitation to invest, but simply information compiled from company press releases and company public information. Information is believed to be reliable, but makes no representation to its accuracy or completeness. LDV does not recommend, warrant, or guarantee the success of any action taken in reliance on statements made in this news release or by any company presentations at the Conference. Due-diligence and professional advice should be sought before making any investment decisions. LDV, nor any of its principles or employees do not hold any stock positions in any of the companies mentioned above.